blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2831592

EP2831592 - BREAST CANCER ASSAY [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  02.08.2019
Database last updated on 30.09.2024
FormerThe patent has been granted
Status updated on  24.08.2018
FormerGrant of patent is intended
Status updated on  05.04.2018
FormerExamination is in progress
Status updated on  04.04.2017
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
The Nottingham Trent University
Clifton Lane
Nottingham NG11 8NS / GB
[2018/39]
Former [2015/06]For all designated states
The Nottingham Trent University
Clifton Lane
Nottingham NG11 8NS / GB
Inventor(s)01 / LINLEY, Adam
School of Science and Technology The Nottingham Trent University
Clifton Lane
Nottingham Nottinghamshire NG11 8NS / GB
02 / MATHIEU, Morgan
School of Science and Technology The Nottingham Trent University
Clifton Lane
Nottingham Nottinghamshire NG11 8NS / GB
03 / MCARDLE, Stephanie
School of Science and Technology The Nottingham Trent University
Clifton Lane
Nottingham Nottinghamshire NG11 8NS / GB
04 / LU, Chungui
School of Science and Technology The Nottingham Trent University
Clifton Lane
Nottingham Nottinghamshire NG11 8NS / GB
05 / REES, Robert
School of Science and Technology The Nottingham Trent University
Clifton Lane
Nottingham Nottinghamshire NG11 8NS / GB
06 / TAT CHAN, Stephen Yan
Department of Clinical Oncology, Nottingham
University Hospitals Trust
- City Hospital Campus
Hucknall Road
Nottingham NG51PB / GB
07 / AHMED ABDEL-FATEH, Tarek Mohamed
18 Chilwell Street
Lenton, Nottingham NG71SB / GB
 [2018/39]
Former [2015/06]01 / LINLEY, Adam
School of Science and Technology The Nottingham Trent University
Clifton Lane
Nottingham Nottinghamshire NG11 8NS / GB
02 / MATHIEU, Morgan
School of Science and Technology The Nottingham Trent University
Clifton Lane
Nottingham Nottinghamshire NG11 8NS / GB
03 / MCARDLE, Stephanie
School of Science and Technology The Nottingham Trent University
Clifton Lane
Nottingham Nottinghamshire NG11 8NS / GB
04 / LU, Chungui
School of Science and Technology The Nottingham Trent University
Clifton Lane
Nottingham Nottinghamshire NG11 8NS / GB
05 / REES, Robert
School of Science and Technology The Nottingham Trent University
Clifton Lane
Nottingham Nottinghamshire NG11 8NS / GB
Representative(s)Potter Clarkson
Chapel Quarter
Mount Street
Nottingham NG1 6HQ / GB
[N/P]
Former [2018/39]Potter Clarkson LLP
The Belgrave Centre
Talbot Street
Nottingham NG1 5GG / GB
Former [2015/06]Elsy, David
Withers & Rogers LLP
4 More London Riverside
London SE1 2AU / GB
Application number, filing date13715406.827.03.2013
[2018/39]
WO2013GB50794
Priority number, dateGB2012000536127.03.2012         Original published format: GB 201205361
[2015/06]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013144616
Date:03.10.2013
Language:EN
[2013/40]
Type: A1 Application with search report 
No.:EP2831592
Date:04.02.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 03.10.2013 takes the place of the publication of the European patent application.
[2015/06]
Type: B1 Patent specification 
No.:EP2831592
Date:26.09.2018
Language:EN
[2018/39]
Search report(s)International search report - published on:EP03.10.2013
ClassificationIPC:G01N33/574, A61P35/00, A61K39/395, A61K31/704
[2018/13]
CPC:
G01N33/57415 (EP,US); A61K31/704 (EP,US); A61P35/00 (EP);
G01N2333/914 (US); G01N2800/52 (EP,US)
Former IPC [2015/06]G01N33/574, A61P35/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/06]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:BRUSTKREBSTEST[2015/06]
English:BREAST CANCER ASSAY[2015/06]
French:TEST DE CANCER DU SEIN[2015/06]
Entry into regional phase01.10.2014National basic fee paid 
01.10.2014Designation fee(s) paid 
01.10.2014Examination fee paid 
Examination procedure01.10.2014Examination requested  [2015/06]
13.05.2015Amendment by applicant (claims and/or description)
14.03.2016Despatch of a communication from the examining division (Time limit: M04)
13.07.2016Reply to a communication from the examining division
24.03.2017Despatch of a communication from the examining division (Time limit: M06)
20.09.2017Reply to a communication from the examining division
05.04.2018Communication of intention to grant the patent
14.08.2018Fee for grant paid
14.08.2018Fee for publishing/printing paid
14.08.2018Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  14.03.2016
Opposition(s)27.06.2019No opposition filed within time limit [2019/36]
Fees paidRenewal fee
29.05.2015Renewal fee patent year 03
31.03.2016Renewal fee patent year 04
21.09.2017Renewal fee patent year 05
09.03.2018Renewal fee patent year 06
Penalty fee
Additional fee for renewal fee
31.03.201503   M06   Fee paid on   29.05.2015
31.03.201705   M06   Fee paid on   21.09.2017
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU27.03.2013
AL26.09.2018
AT26.09.2018
CY26.09.2018
CZ26.09.2018
DK26.09.2018
EE26.09.2018
ES26.09.2018
FI26.09.2018
HR26.09.2018
IT26.09.2018
LT26.09.2018
LV26.09.2018
MC26.09.2018
MK26.09.2018
NL26.09.2018
PL26.09.2018
RO26.09.2018
RS26.09.2018
SE26.09.2018
SI26.09.2018
SK26.09.2018
SM26.09.2018
TR26.09.2018
BG26.12.2018
NO26.12.2018
GR27.12.2018
IS26.01.2019
PT26.01.2019
IE27.03.2019
LU27.03.2019
MT27.03.2019
BE31.03.2019
CH31.03.2019
LI31.03.2019
[2022/31]
Former [2021/33]HU27.03.2013
AL26.09.2018
AT26.09.2018
CY26.09.2018
CZ26.09.2018
DK26.09.2018
EE26.09.2018
ES26.09.2018
FI26.09.2018
HR26.09.2018
IT26.09.2018
LT26.09.2018
LV26.09.2018
MC26.09.2018
NL26.09.2018
PL26.09.2018
RO26.09.2018
RS26.09.2018
SE26.09.2018
SI26.09.2018
SK26.09.2018
SM26.09.2018
TR26.09.2018
BG26.12.2018
NO26.12.2018
GR27.12.2018
IS26.01.2019
PT26.01.2019
IE27.03.2019
LU27.03.2019
MT27.03.2019
BE31.03.2019
CH31.03.2019
LI31.03.2019
Former [2021/26]AL26.09.2018
AT26.09.2018
CY26.09.2018
CZ26.09.2018
DK26.09.2018
EE26.09.2018
ES26.09.2018
FI26.09.2018
HR26.09.2018
IT26.09.2018
LT26.09.2018
LV26.09.2018
MC26.09.2018
NL26.09.2018
PL26.09.2018
RO26.09.2018
RS26.09.2018
SE26.09.2018
SI26.09.2018
SK26.09.2018
SM26.09.2018
TR26.09.2018
BG26.12.2018
NO26.12.2018
GR27.12.2018
IS26.01.2019
PT26.01.2019
IE27.03.2019
LU27.03.2019
MT27.03.2019
BE31.03.2019
CH31.03.2019
LI31.03.2019
Former [2020/29]AL26.09.2018
AT26.09.2018
CZ26.09.2018
DK26.09.2018
EE26.09.2018
ES26.09.2018
FI26.09.2018
HR26.09.2018
IT26.09.2018
LT26.09.2018
LV26.09.2018
MC26.09.2018
NL26.09.2018
PL26.09.2018
RO26.09.2018
RS26.09.2018
SE26.09.2018
SI26.09.2018
SK26.09.2018
SM26.09.2018
TR26.09.2018
BG26.12.2018
NO26.12.2018
GR27.12.2018
IS26.01.2019
PT26.01.2019
IE27.03.2019
LU27.03.2019
MT27.03.2019
BE31.03.2019
CH31.03.2019
LI31.03.2019
Former [2020/17]AL26.09.2018
AT26.09.2018
CZ26.09.2018
DK26.09.2018
EE26.09.2018
ES26.09.2018
FI26.09.2018
HR26.09.2018
IT26.09.2018
LT26.09.2018
LV26.09.2018
MC26.09.2018
NL26.09.2018
PL26.09.2018
RO26.09.2018
RS26.09.2018
SE26.09.2018
SI26.09.2018
SK26.09.2018
SM26.09.2018
TR26.09.2018
BG26.12.2018
NO26.12.2018
GR27.12.2018
IS26.01.2019
PT26.01.2019
IE27.03.2019
LU27.03.2019
BE31.03.2019
CH31.03.2019
LI31.03.2019
Former [2020/11]AL26.09.2018
AT26.09.2018
CZ26.09.2018
DK26.09.2018
EE26.09.2018
ES26.09.2018
FI26.09.2018
HR26.09.2018
IT26.09.2018
LT26.09.2018
LV26.09.2018
MC26.09.2018
NL26.09.2018
PL26.09.2018
RO26.09.2018
RS26.09.2018
SE26.09.2018
SI26.09.2018
SK26.09.2018
SM26.09.2018
BG26.12.2018
NO26.12.2018
GR27.12.2018
IS26.01.2019
PT26.01.2019
IE27.03.2019
LU27.03.2019
BE31.03.2019
CH31.03.2019
LI31.03.2019
Former [2020/09]AL26.09.2018
AT26.09.2018
CZ26.09.2018
DK26.09.2018
EE26.09.2018
ES26.09.2018
FI26.09.2018
HR26.09.2018
IT26.09.2018
LT26.09.2018
LV26.09.2018
MC26.09.2018
NL26.09.2018
PL26.09.2018
RO26.09.2018
RS26.09.2018
SE26.09.2018
SI26.09.2018
SK26.09.2018
SM26.09.2018
BG26.12.2018
NO26.12.2018
GR27.12.2018
IS26.01.2019
PT26.01.2019
IE27.03.2019
LU27.03.2019
Former [2020/01]AL26.09.2018
AT26.09.2018
CZ26.09.2018
DK26.09.2018
EE26.09.2018
ES26.09.2018
FI26.09.2018
HR26.09.2018
IT26.09.2018
LT26.09.2018
LV26.09.2018
MC26.09.2018
NL26.09.2018
PL26.09.2018
RO26.09.2018
RS26.09.2018
SE26.09.2018
SI26.09.2018
SK26.09.2018
SM26.09.2018
BG26.12.2018
NO26.12.2018
GR27.12.2018
IS26.01.2019
PT26.01.2019
LU27.03.2019
Former [2019/50]AL26.09.2018
AT26.09.2018
CZ26.09.2018
DK26.09.2018
EE26.09.2018
ES26.09.2018
FI26.09.2018
HR26.09.2018
IT26.09.2018
LT26.09.2018
LV26.09.2018
MC26.09.2018
NL26.09.2018
PL26.09.2018
RO26.09.2018
RS26.09.2018
SE26.09.2018
SI26.09.2018
SK26.09.2018
SM26.09.2018
BG26.12.2018
NO26.12.2018
GR27.12.2018
IS26.01.2019
PT26.01.2019
Former [2019/46]AL26.09.2018
AT26.09.2018
CZ26.09.2018
DK26.09.2018
EE26.09.2018
ES26.09.2018
FI26.09.2018
HR26.09.2018
IT26.09.2018
LT26.09.2018
LV26.09.2018
MC26.09.2018
NL26.09.2018
PL26.09.2018
RO26.09.2018
RS26.09.2018
SE26.09.2018
SK26.09.2018
SM26.09.2018
BG26.12.2018
NO26.12.2018
GR27.12.2018
IS26.01.2019
PT26.01.2019
Former [2019/34]AL26.09.2018
AT26.09.2018
CZ26.09.2018
DK26.09.2018
EE26.09.2018
ES26.09.2018
FI26.09.2018
HR26.09.2018
IT26.09.2018
LT26.09.2018
LV26.09.2018
NL26.09.2018
PL26.09.2018
RO26.09.2018
RS26.09.2018
SE26.09.2018
SK26.09.2018
SM26.09.2018
BG26.12.2018
NO26.12.2018
GR27.12.2018
IS26.01.2019
PT26.01.2019
Former [2019/26]AL26.09.2018
AT26.09.2018
CZ26.09.2018
EE26.09.2018
ES26.09.2018
FI26.09.2018
HR26.09.2018
IT26.09.2018
LT26.09.2018
LV26.09.2018
NL26.09.2018
PL26.09.2018
RO26.09.2018
RS26.09.2018
SE26.09.2018
SK26.09.2018
SM26.09.2018
BG26.12.2018
NO26.12.2018
GR27.12.2018
IS26.01.2019
PT26.01.2019
Former [2019/23]AL26.09.2018
AT26.09.2018
CZ26.09.2018
EE26.09.2018
ES26.09.2018
FI26.09.2018
HR26.09.2018
IT26.09.2018
LT26.09.2018
LV26.09.2018
NL26.09.2018
PL26.09.2018
RO26.09.2018
RS26.09.2018
SE26.09.2018
SK26.09.2018
BG26.12.2018
NO26.12.2018
GR27.12.2018
IS26.01.2019
Former [2019/22]AL26.09.2018
CZ26.09.2018
FI26.09.2018
HR26.09.2018
IT26.09.2018
LT26.09.2018
LV26.09.2018
NL26.09.2018
PL26.09.2018
RO26.09.2018
RS26.09.2018
SE26.09.2018
BG26.12.2018
NO26.12.2018
GR27.12.2018
IS26.01.2019
Former [2019/21]AL26.09.2018
FI26.09.2018
HR26.09.2018
IT26.09.2018
LT26.09.2018
LV26.09.2018
NL26.09.2018
RS26.09.2018
SE26.09.2018
BG26.12.2018
NO26.12.2018
GR27.12.2018
IS26.01.2019
Former [2019/20]AL26.09.2018
FI26.09.2018
HR26.09.2018
LT26.09.2018
LV26.09.2018
NL26.09.2018
RS26.09.2018
SE26.09.2018
BG26.12.2018
NO26.12.2018
GR27.12.2018
Former [2019/12]AL26.09.2018
FI26.09.2018
HR26.09.2018
LT26.09.2018
LV26.09.2018
RS26.09.2018
SE26.09.2018
BG26.12.2018
NO26.12.2018
GR27.12.2018
Former [2019/11]FI26.09.2018
HR26.09.2018
LT26.09.2018
RS26.09.2018
SE26.09.2018
BG26.12.2018
NO26.12.2018
GR27.12.2018
Former [2019/10]FI26.09.2018
LT26.09.2018
RS26.09.2018
SE26.09.2018
BG26.12.2018
NO26.12.2018
GR27.12.2018
Former [2019/08]FI26.09.2018
LT26.09.2018
NO26.12.2018
Former [2019/07]LT26.09.2018
Cited inInternational search[Y]WO9953061  (LUDWIG INST CANCER RES [US]) [Y] 1-12* p. 36-62, example 1, table V *;
 [Y]WO2005005601  (UNIV MICHIGAN [US], et al) [Y] 1-12 * tab. 4 and claims *;
 [XYI]WO2005039634  (GLAXOSMITHKLINE BIOLOG SA [BE], et al) [X] 9,11 * p. 10 and claims * [Y] 8,12 [I] 10;
 [Y]WO2011109637  (KOO FOUNDATION SUN YAT SEN CANCER CT [CN], et al) [Y] 4-8 * claims 1-47 *;
 [Y]WO2011130495  (NUVERA BIOSCIENCES INC [US], et al) [Y] 4-8 * example 9 *;
 [XPI]  - ABDEL-FATAH T M A ET AL, "HAGE (DDX43) Protein Expression is a Powerful Independent Biomarker of Poor Clinical Outcome of Breast Cancer (BC) and Could be a Potential Therapeutic Target for ER Negative BC", JOURNAL OF PATHOLOGY, JOHN WILEY & SONS LTD, GB, (20120901), vol. 228, no. Suppl. 1, ISSN 0022-3417, page S11, XP009170982 [XP] 1-7 * abstract * [I] 8-12
 [I]  - LUCA GIANNI ET AL, "Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial", THE LANCET ONCOLOGY, (20120101), vol. 13, no. 1, doi:10.1016/S1470-2045(11)70336-9, ISSN 1470-2045, pages 25 - 32, XP055052201 [I] 12 * the whole document, see especially p. 25-27 *

DOI:   http://dx.doi.org/10.1016/S1470-2045(11)70336-9
 [XY]  - MATHIEU MORGAN G ET AL, "HAGE, a cancer/testis antigen expressed at the protein level in a variety of cancers", CANCER IMMUNITY, ACADEMY OF CANCER IMMUNOLOGY, CH, (20100101), vol. 10, no. 2, ISSN 1424-9634, pages 1 - 8, XP009171017 [X] 11 * p. 1 and 5 * [Y] 8-10
by applicant   - MATHIEU ET AL., CANCER IMMUNITY, (2010), vol. 10, pages 2 - 9
    - BREAST. DIS, (2000), vol. 11, pages 113 - 124
    - WOLFF AC ET AL., J.CLIN.ONCOL., (2007), vol. 25, pages 118 - 145
    - DENT R, CLIN. CANCER RES., (2007), vol. 13, pages 4429 - 34
    - GUARNERI V ET AL., ANN. ONCOL., (2009), vol. 20, pages 1193 - 1198
    - KYTE JA ET AL., CLIN. CANCER RES., (2011), vol. 17, pages 4568 - 4580
    - NENINGER E ET AL., J. IMMUNOTHER, (2009), vol. 32, pages 92 - 99
    - SAMPSON JH ET AL., NEURO. ONCOL., (2010), vol. 13, pages 324 - 333
    - ZHOU ET AL., J. EXP. CLIN. CANCER RES., (2011), vol. 20, page 2
    - WEIR GM, CANCERS, (2011), vol. 3, pages 3114 - 3142
    - NAT. REV. IMMUNOL., (2008), vol. 8, pages 59 - 73
    - GLUCK S; MAMOUNAS T, "Improving outcomes in early-stage breast cancer", ONCOLOGY (WILLISTON PARK, vol. 24, pages 1 - 15
    - CLARKE M; COATES AS; DARBY SC ET AL., "Adjuvant chemotherapy in oestrogen- receptor-poor breast cancer: patient-level meta-analysis of randomised trials", LANCET, (2008), vol. 371, doi:doi:10.1016/S0140-6736(08)60069-0, pages 29 - 40, XP022408838

DOI:   http://dx.doi.org/10.1016/S0140-6736(08)60069-0
    - DOTAN E; GOLDSTEIN LJ, "Optimizing chemotherapy regimens for patients with early-stage breast cancer", CLIN BREAST CANCER, vol. 10, no. 1, pages E8 - 15
    - HARRIS L; FRITSCHE H; MENNEL R ET AL., "American Society of Clinical Oncology 2007 update of recommendations for the use of tumour markers in breast cancer", J CLIN ONCOL, (2007), vol. 25, doi:doi:10.1200/JCO.2007.14.2364, pages 5287 - 312, XP055419000

DOI:   http://dx.doi.org/10.1200/JCO.2007.14.2364
    - HARBECK N; SALEM M; NITZ U ET AL., "Personalized treatment of early-stage breast cancer: present concepts and future directions", CANCER TREAT REV, vol. 36, doi:doi:10.1016/j.ctrv.2010.04.007, pages 584 - 94, XP027487294

DOI:   http://dx.doi.org/10.1016/j.ctrv.2010.04.007
    - MARTELANGE V; DE SMET C; DE PLAEN E ET AL., "Identification on a Human Sarcoma of Two New Genes with Tumor-specific Expression", CANCER RESEARCH, (2000), vol. 60, pages 3848 - 3855, XP002256958
    - ADAMS SP; SAHOTA SS; MIJOVIC A ET AL., "Frequent expression of HAGE in presentation chronic myeloid leukaemias", LEUKEMIA, (2002), vol. 16, no. 11, pages 2238 - 42
    - MATHIEU MG; KNIGHTS AJ; PAWELEC G ET AL., "HAGE, a cancer/testis antigen with potential for melanoma immunotherapy: identification of several MHC class I/II HAGE-derived immunogenic peptides", CANCER IMMUNOLLMMUNOTHER, (2007), vol. 56, doi:doi:10.1007/s00262-007-0331-2, pages 1885 - 1895, XP019561038

DOI:   http://dx.doi.org/10.1007/s00262-007-0331-2
    - PINDER SE; ELLIS 10; GALEA M ET AL., "Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up", HISTOPATHOLOGY, (1994), vol. 24, pages 41 - 7
    - ELSTON CW, "Ellis 10: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up", HISTOPATHOLOGY, (1991), vol. 19, pages 403 - 10
    - MCSHANE LM; ALTMAN DG; SAUERBREI W ET AL., "Reporting recommendations for tumour marker prognostic studies (REMARK", J NATL CANCER INST, (2005), vol. 97, pages 1180 - 4
    - ABDEL-FATAH TM; POWE DG; BALL G ET AL., "Proposal for a modified grading system based on mitotic index and Bcl2 provides objective determination of clinical outcome for patients with breast cancer", J PATHOL, (2010), vol. 222, pages 388 - 99
    - ABDEL-FATAH TM; POWE DG; AGBOOLA J ET AL., "The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers", J PATHOL, (2010), vol. 220, pages 419 - 34
    - CALLAGY GM; PHAROAH PD; PINDER SE ET AL., "Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index", CLIN CANCER RES, (2006), vol. 12, pages 2468 - 75
    - TAN DS; MARCHIO C; JONES RL ET AL., "Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients", BREAST CANCER RES TREAT, (2008), vol. 111, pages 27 - 44
    - SAUTER G; LEE J; BARTLETT JM ET AL., "Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations", J CLIN ONCOL, (2009), vol. 27, pages 1323 - 33
    - HOLM S, "A simple sequentially rejective multiple test procedure", SCAND J STAT, (1979), vol. 6, pages 65 - 70
    - LURQUIN C; LETHE B; DE PLAEN E ET AL., "Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumour antigen", J EXP MED, (2005), vol. 201, doi:doi:10.1084/jem.20041378, pages 249 - 57, XP002415288

DOI:   http://dx.doi.org/10.1084/jem.20041378
    - ROMAN-GOMEZ J; JIMENEZ-VELASCO A; AGIRRE X ET AL., "Epigenetic regulation of human cancer/testis antigen gene, HAGE, in chronic myeloid leukaemia", HAEMATOLOGICA, (2007), vol. 92, pages 153 - 62
    - OTTE M; ZAFRAKAS M; RIETHDORF L ET AL., "MAGE-A gene expression pattern in primary breast cancer", CANCER RES, (2001), vol. 61, pages 6682 - 7, XP002277597
    - KURASHIGE T; NOGUCHI Y; SAIKAT ET AL., "NY-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumour grade", CANCER RES, (2001), vol. 61, pages 4671 - 4
    - YAKIREVICH E; SABO E; LAVIE O ET AL., "Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms", CLIN CANCER RES, (2003), vol. 9, pages 6453 - 60, XP003022712
    - KIM YI; GIULIANO A; HATCH KD ET AL., "Global DNA hypomethylation increases progressively in cervical dysplasia and carcinoma", CANCER, (1994), vol. 74, pages 893 - 9, XP008048083
    - QU G; DUBEAU L; NARAYAN A ET AL., "Satellite DNA hypomethylation vs. overall genomic hypomethylation in ovarian epithelial tumours of different malignant potential", MUTAT RES, (1999), vol. 423, doi:doi:10.1016/S0027-5107(98)00229-2, pages 91 - 101, XP002265794

DOI:   http://dx.doi.org/10.1016/S0027-5107(98)00229-2
    - SOARES J; PINTO AE; CUNHA CV ET AL., "Global DNA hypomethylation in breast carcinoma: correlation with prognostic factors and tumour progression", CANCER, (1999), vol. 85, pages 112 - 8
    - PIYATHILAKE CJ; FROST AR; BELL WC ET AL., "Altered global methylation of DNA: an epigenetic difference in susceptibility for lung cancer is associated with its progression", HUM PATHOL, (2001), vol. 32, pages 856 - 62
    - ZHOU L; BAO YL; ZHANG Y; WU Y; YU CL ET AL., "Knockdown of TSP50 inhibits cell proliferation and induces apoptosis in P19 cells", IUBMB LIFE, (2010), vol. 62, pages 825 - 832
    - IGGO R; PICKSLEY S; SOUTHGATE J ET AL., "Identification of a putative RNA helicase in E. coli", NUCLEIC ACIDS RES, (1990), vol. 18, pages 5413 - 7, XP002120088
    - YANG L; LIN C; LIU ZR, "Phosphorylations of DEAD box p68 RNA helicase are associated with cancer development and cell proliferation", MOL CANCER RES, (2005), vol. 3, doi:doi:10.1158/1541-7786.MCR-05-0022, pages 355 - 63, XP002993992

DOI:   http://dx.doi.org/10.1158/1541-7786.MCR-05-0022
    - CHEN Q; LIN J; QIAN J; YAO DM ET AL., "Gene expression of helicase antigen in patients with acute and chronic myeloid leukaemia", ZHONGGUO SHI YAN XUE YE XUEZAZHI, (2011), vol. 19, pages 1171 - 5
    - ZHENG L; XIE G; DUAN G ET AL., "High expression of testes-specific protease 50 is associated with poor prognosis in colorectal carcinoma", PLOS ONE, (2011), vol. 6, page E22203
    - KIM J; REBER HA; HINES OJ ET AL., "The clinical significance of MAGEA3 expression in pancreatic cancer", INT J CANCER, (2006), vol. 118, pages 2269 - 2275
    - RIENER MO; WILD PJ; SOLL C ET AL., "Frequent expression of the novel cancer testis antigen MAGE-C2/CT-10 in hepatocellular carcinoma", INT J CANCER, (2009), vol. 124, pages 352 - 357
    - VELAZQUEZ EF; JUNGBLUTH AA; YANCOVITZ M ET AL., "Expression of the cancer/testis antigen NY-ESO-1 in primary and metastaticmalignant melanoma (MM)-correlation with prognostic factors", CANCER IMMUN, (2007), vol. 7, page 11
    - SHIN S; ROSSOW KL; GRANDE JP ET AL., "Involvement of RNA helicases p68 and p72 in colon cancer", CANCER RESEARCH, (2007), vol. 67, pages 7572 - 7578
    - WORTHAM NC; AHAMED E; NICOL SM ET AL., "The DEAD-box protein p72 regulates ER alpha-/oestrogen-dependent transcription and cell growth, and is associated with improved survival in ER alpha-positive BC", ONCOGENE, (2009), vol. 28, pages 4053 - 4064
    - ISSA JP; GARCIA-MANERO G; GILES FJ ET AL., "Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies", BLOOD, (2004), vol. 103, pages 1635 - 40
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.